CD47 in Osteosarcoma: Correlation with Metastasis and Macrophage-Mediated Phagocytosis

Yunmi Ko1, Seog-Yun Park2, Jong Woong Park3

  • 1Department of Pediatrics, National Cancer Center, Goyang 10408, Republic of Korea.

Cells
|November 27, 2024
PubMed

Insights

CD47 protein, a "don't eat me" signal, is present in some osteosarcoma tumors and may promote metastasis. Targeting CD47 could enhance macrophage phagocytosis, offering a potential immunotherapy strategy for osteosarcoma.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • CD47 acts as a "don't eat me" signal, preventing macrophage phagocytosis.
  • Cancer cells can exploit CD47 to evade immune surveillance.
  • Osteosarcoma is a primary bone cancer with significant metastatic potential.

Purpose of the Study:

  • To investigate CD47 expression in osteosarcoma.
  • To correlate CD47 expression with clinicopathological features.
  • To explore the therapeutic potential of targeting CD47 in osteosarcoma.

Main Methods:

  • Retrospective analysis of 24 osteosarcoma biopsy samples.
  • Immunohistochemistry to detect CD47 protein expression.
  • In vitro assays including cell viability, apoptosis, migration, and phagocytosis assays using CD47 antibody (B6H12).

Main Results:

  • CD47 protein was detected in 20.8% of osteosarcoma samples.
  • CD47 positivity correlated with metastasis at diagnosis and older patient age.
  • CD47 antibody enhanced macrophage phagocytosis of osteosarcoma cells in vitro and inhibited tumor cell migration.

Conclusions:

  • CD47 expression in osteosarcoma is associated with metastatic potential.
  • Targeting CD47 may represent a viable immunotherapeutic strategy for osteosarcoma.
  • Further research is needed to elucidate CD47's role in osteosarcoma progression and metastasis.